Cytovia Raises $45 Million for JV to Develop NK Products in China

Cytovia Therapeutics of Florida established a JV in Shanghai with an initial $45 million to develop its “off-the-shelf” CAR products in China . The JV, CytoLynx, will pay up to $400 million in milestones to Cytovia as it develops the parent company's products. Cytovia is developing gene-edited iNK and CAR-iNK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager antibodies. The $45 million initial funding was led by TF Capital and joined by other China venture capital firms. More details.... Share this with colleagues: // //